Antismoking groups sued the US government over the long-awaited menthol cigarette ban; the fill rate for Adderall and Vyvanse dropped more than 10% in 2 years despite soaring demand; the Biden administration has responded to offers from the manufacturers of drugs selected for Medicare pricing negotiations.
Antismoking groups sued the US government on Tuesday over the long-awaited menthol cigarette ban, which the Biden administration has been delaying for months, according to the Associated Press. This lawsuit is the latest effort to force the government to ban menthol cigarettes, which are disproportionately used by young people and Black smokers; advocates are concerned that the federal plan could be derailed by election-year politics. Late last year, White House officials said they would take until March to review the rule. After the March deadline passed, 3 nonprofit groups, including Action on Smoking and Health, filed their lawsuit in a California federal court. A lawyer who helped file the lawsuit said the government will have about 2 months to respond.
A recent analysis found that the fill rate for Adderall and Vyvanse, 2 commonly prescribed drugs for attention-deficit/hyperactivity disorder (ADHD), dropped more than 10% in 2 years despite soaring demand, according to Axios. The ADHD drug shortage has occurred for nearly 18 months with no clear end in sight and is among many generic medicine shortages in recent years. Likely drivers of the shortages include drug production caps and pandemic-driven demand increases. The problem has recently been getting attention on Capitol Hill and from federal regulators. On Tuesday, HHS said in a white paper that statutory changes and more funding are needed for “more impactful and enduring solutions” than the ones it has already taken to address the shortages.
The Biden administration announced Tuesday that it has responded to offers from the manufacturers of 10 high-cost drugs selected for the Medicare drug pricing negotiations but provided no further details, according to Reuters. CMS picked the first 10 drugs for negotiation in August and sent its initial price offers in February. The companies had until March 1 to respond, and all did so. Each company can meet with CMS up to 3 times for further negotiations before a final price is announced on August 1. However, the negotiated prices will not come into effect until 2026. The drugs selected for negotiation are manufactured by Bristol Myers Squibb, Johnson & Johnson, Eli Lilly, Novo Nordisk, Pfizer, Merck & Co, AbbVie, Amgen, and Boehringer Ingelheim.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Traditional Medicare Supplemental Insurance and the Rise of Medicare Advantage
May 7th 2024Rising Medicare Advantage enrollment occurred alongside declines in enrollment in traditional Medicare with employer-sponsored supplemental coverage and traditional Medicare without supplemental coverage.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Senate Finance Committee has introduced bipartisan legislation that proposes using Medicaid and Medicare programs to help prevent and reduce generic drug shortages; US indicators for COVID-19, flu, and respiratory syncytial virus (RSV) declined further last week; findings from a recent study reveal growing disparities in child death rates across racial and ethnic groups.
Read More
Access Denied: CMS’ Action Hurts Patients With Cancer in Rural America
May 6th 2024CMS rules hindered the access of rural patients with cancer to medically integrated pharmacies in 2023. The authors discuss the impact on equity in health care, emphasizing the need for regulatory change.
Read More